VEGFR-2 as a novel predictor of survival in gastric cancer: a systematic review and meta-analysis

Publication date: Available online 14 February 2018
Source:Pathology - Research and Practice
Author(s): Teng Li, Jing Yu, Xinyu Luo, Weiguo Ren, Yue Zhang, Bangwei Cao
BackgroundExpression of VEGFRs may affect cancer prognosis. The aim of this work is to evaluate the prognostic significance of VEGFRs of patients with gastric cancer.MethodsThe databases PubMed, Embase, Web of Science, and Cochrane Library as well as ASCO and ESMO were searched systematically for articles reporting the prognostic significance of tissue VEGFRs in gastric cancer. The statistical analyses were carried out using Stata version 12.0.ResultsA total of 8 articles comprising 950 patients were eligible for meta-analysis. The combined HR of studies evaluating total VEGFRs overexpression was 1.42 (95% CI 1.01-2.00, P = 0.044), suggesting that it had prognosis significance in overall survival of gastric cancer. Subgroup analysis showed that it was VEGFR-2 (HR 1.81, 95%CI 1.31–2.49, P < 0.001) but not VEGFR-3 (HR 0.91, 95%CI 0.45–1.82, P = 0.787) overexpression was associated with an increased risk of median overall survival (mOS) and it can be a potentially predictive biomarker for gastric cancer.ConclusionsVEGFR-2 overexpression is a promising negative prognosis predictor for patients with gastric cancer. The prognosis significance of VEGFR-3 still need further study.



http://ift.tt/2BYVr4w